☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC sitagliptin review updated

The Midlands Therapeutic Review and Advisory Committee has published an updated review of sitagliptin (Januvia®).

This review places sitagliptin as having a lower place in therapy but supported by stronger evidence. In combination with other hypoglycaemic drugs it has been shown to lower HbA1c to a greater extent than placebo and has been shown to be non-inferior to glipizide.

MTRAC recommends that, "sitagliptin is suitable for prescribing in primary care upon the advice of a specialist or a GP with a special interest in diabetes". This update notes that sitagliptin can now be used, within license, in combination with metformin and a sulphonylurea for patients who fail to achieve adequate glycaemic control.

Action: Clinicians should be aware of the licence extension for sitagliptin. This drug is still new to the market and should be used cautiously; any suspected adverse drug reactions should be reported through the YellowCard system.

Share 'MTRAC sitagliptin review updated' by emailShare 'MTRAC sitagliptin review updated' on FacebookShare 'MTRAC sitagliptin review updated' on TwitterShare 'MTRAC sitagliptin review updated' on MastodonShare 'MTRAC sitagliptin review updated' on LinkedInShare 'MTRAC sitagliptin review updated' on reddit

atomic-wealth

One Comment to “MTRAC sitagliptin review updated”

  1. [...] places sitagliptin as having a lower place in therapy but supported by stronger evidence. It was previously known that in combination with other hypoglycaemic drugs it has been shown to lower HbA1c to a greater [...]

    Pingback by Prescribing Advice for GPs » MTRAC sitagliptin review updated — April 23, 2010 #
    Reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.